Cullinan Oncology, Inc. Files 2023 Annual Report on Form 10-K

Ticker: CGEM · Form: 10-K · Filed: Mar 14, 2024 · CIK: 1789972

Cullinan Oncology, Inc. 10-K Filing Summary
FieldDetail
CompanyCullinan Oncology, Inc. (CGEM)
Form Type10-K
Filed DateMar 14, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Cullinan Oncology, Biotechnology, Annual Report, Financials

TL;DR

<b>Cullinan Oncology, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations.</b>

AI Summary

Cullinan Oncology, Inc. (CGEM) filed a Annual Report (10-K) with the SEC on March 14, 2024. Cullinan Oncology, Inc. filed its 2023 Form 10-K on March 14, 2024. The company's fiscal year ends on December 31st. The filing covers the period ending December 31, 2023. Cullinan Oncology, Inc. is in the Biological Products industry. The company's principal executive offices are located in Cambridge, MA.

Why It Matters

For investors and stakeholders tracking Cullinan Oncology, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cullinan Oncology's financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and risk factors within the 10-K are essential for understanding the company's current financial position, including its assets, liabilities, and equity, as well as potential challenges it faces in the biotechnology sector.

Risk Assessment

Risk Level: medium — Cullinan Oncology, Inc. shows moderate risk based on this filing. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and market adoption of its products, as indicated by its focus on research and development expenses and potential collaborative arrangements.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Cullinan Oncology's financial position and the inherent risks in drug development.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Period of report)
  • 2024-03-14 — Filing Date (Date of filing)
  • 001-39856 — SEC File Number (SEC filing details)
  • 0000950170-24-031143 — Accession Number (Filing identifier)

Key Players & Entities

  • Cullinan Oncology, Inc. (company) — Filer name
  • 2023 (date) — Reporting period
  • March 14, 2024 (date) — Filing date
  • Cambridge, MA (location) — Business address
  • BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) (industry) — Standard Industrial Classification
  • Cullinan Management, Inc. (company) — Former company name
  • Cullinan Oncology, LLC (company) — Former company name
  • Massachusetts Institute of Technology (company) — Collaborative arrangement

FAQ

When did Cullinan Oncology, Inc. file this 10-K?

Cullinan Oncology, Inc. filed this Annual Report (10-K) with the SEC on March 14, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Cullinan Oncology, Inc. (CGEM).

Where can I read the original 10-K filing from Cullinan Oncology, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cullinan Oncology, Inc..

What are the key takeaways from Cullinan Oncology, Inc.'s 10-K?

Cullinan Oncology, Inc. filed this 10-K on March 14, 2024. Key takeaways: Cullinan Oncology, Inc. filed its 2023 Form 10-K on March 14, 2024.. The company's fiscal year ends on December 31st.. The filing covers the period ending December 31, 2023..

Is Cullinan Oncology, Inc. a risky investment based on this filing?

Based on this 10-K, Cullinan Oncology, Inc. presents a moderate-risk profile. The company operates in the highly competitive and regulated biotechnology sector, facing risks related to clinical trial success, regulatory approvals, and market adoption of its products, as indicated by its focus on research and development expenses and potential collaborative arrangements.

What should investors do after reading Cullinan Oncology, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand Cullinan Oncology's financial position and the inherent risks in drug development. The overall sentiment from this filing is neutral.

Risk Factors

  • Regulatory Risks [high — regulatory]: The company is subject to extensive government regulation, including the FDA, which can impact product development, manufacturing, and marketing.
  • Market Adoption and Competition [high — market]: The success of the company's products depends on market acceptance and competition from other biotechnology firms.
  • Funding and Liquidity [medium — financial]: The company may require significant additional capital to fund its operations and product development, posing liquidity risks.
  • Clinical Trial Risks [high — operational]: Clinical trials are inherently uncertain and may not demonstrate the safety or efficacy of the company's drug candidates.

Key Dates

  • 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K filing.
  • 2024-03-14: Filing Date — Date Cullinan Oncology, Inc. submitted its 10-K to the SEC.

Filing Stats: 4,402 words · 18 min read · ~15 pages · Grade level 16.9 · Accepted 2024-03-14 07:22:00

Key Financial Figures

  • $0.0001 — ch registered Common Stock, par value $0.0001 per share CGEM The Nasdaq Global Se

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 51 Item 1B. Unresolved Staff Comments 101 Item 1C. Cybersecurity 101 Item 2.

Properties

Properties 102 Item 3.

Legal Proceedings

Legal Proceedings 102 Item 4. Mine Safety Disclosures 102 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 103 Item 6. Reserved 103 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 104 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 113 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 113 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 113 Item 9A.

Controls and Procedures

Controls and Procedures 113 Item 9B. Other Information 114 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 114 PART III Item 10. Directors, Executive Officers and Corporate Governance 115 Item 11.

Executive Compensation

Executive Compensation 118 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 125 Item 13. Certain Relationships and Related Transactions, and Director Independence 129 Item 14. Principal Accountant Fees and Services 131 PART IV Item 15. Exhibits and Financial Statement Schedules 132 Item 16. Form 10-K Summary 132 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, and expected market growth are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors

B usiness

Item 1. B usiness. Overview We are a clinical-stage biopharmaceutical company focused on developing modality-agnostic targeted oncology therapies. Our mission is creating new standards of care for patients. Our strategy is to identify high-impact cancer targets, which we define as those that play key roles as either oncogenic drivers or immune system activators, and then select what we believe is the optimal therapeutic modality for those targets. We apply a rigorous and differentiated approach to drug development, which is guided by the following core elements: Rapidly advance only candidates that we believe have first- and/or best-in-class potential. Seek clear evidence of monotherapy activity early in preclinical and clinical development, which we believe will de-risk later stage drug development. Remain open to finding what we believe are the optimal modalities and drug candidates either through in-house discovery or through licensing and collaborations. Using this strategy, we have built a broad and deep pipeline of targeted oncology programs that includes six distinct clinical-stage product candidates. Our current pipeline is summarized in the diagram and bullets below: Our lead unpartnered program, CLN-619, is a monoclonal antibody designed to stabilize expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by both cytotoxic innate and adaptive immune cells. CLN-619 is being investigated as both monotherapy and in combination with checkpoint inhibitor therapy in an ongoing Phase 1 clinical trial in patients with advanced solid tumors. We intend to present initial data from the checkpoint inhibitor therapy combination dose escalation module of the clinical trial, as well as updated data from the monotherapy dose escalation module, in the second quarter of 2024. Initial data from the disease specific expansion cohorts are anticipated in the first half of 2025. Separately, in February 2024, the United States ("U.S.") Fo

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.